Phase­Bio rais­es $34M to test or­phan dis­ease strat­e­gy — fo­cus­ing first on As­traZeneca drug

Af­ter spend­ing the past three years repo­si­tion­ing it­self as an or­phan dis­ease-fo­cused biotech, Phase­Bio is ready to roll with a fresh $34 mil­lion raise. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.